JP2024511163A5 - - Google Patents

Info

Publication number
JP2024511163A5
JP2024511163A5 JP2023558765A JP2023558765A JP2024511163A5 JP 2024511163 A5 JP2024511163 A5 JP 2024511163A5 JP 2023558765 A JP2023558765 A JP 2023558765A JP 2023558765 A JP2023558765 A JP 2023558765A JP 2024511163 A5 JP2024511163 A5 JP 2024511163A5
Authority
JP
Japan
Prior art keywords
amino acid
adenosine deaminase
modifications
group
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022050 external-priority patent/WO2022204574A1/en
Publication of JP2024511163A publication Critical patent/JP2024511163A/ja
Publication of JP2024511163A5 publication Critical patent/JP2024511163A5/ja
Pending legal-status Critical Current

Links

JP2023558765A 2021-03-26 2022-03-25 アデノシンデアミナーゼバリアント及びその使用 Pending JP2024511163A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166778P 2021-03-26 2021-03-26
US63/166,778 2021-03-26
US202163229057P 2021-08-03 2021-08-03
US63/229,057 2021-08-03
PCT/US2022/022050 WO2022204574A1 (en) 2021-03-26 2022-03-25 Adenosine deaminase variants and uses thereof

Publications (2)

Publication Number Publication Date
JP2024511163A JP2024511163A (ja) 2024-03-12
JP2024511163A5 true JP2024511163A5 (https=) 2025-04-01

Family

ID=83397962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558765A Pending JP2024511163A (ja) 2021-03-26 2022-03-25 アデノシンデアミナーゼバリアント及びその使用

Country Status (8)

Country Link
US (1) US20240158775A1 (https=)
EP (1) EP4313118A4 (https=)
JP (1) JP2024511163A (https=)
KR (1) KR20240004276A (https=)
AU (1) AU2022246176A1 (https=)
BR (1) BR112023019539A2 (https=)
CA (1) CA3214494A1 (https=)
WO (1) WO2022204574A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
AU2020215730A1 (en) 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
EP4705444A2 (en) * 2023-05-04 2026-03-11 Technische Universität Dresden Highly active crispr base editors obtained through cas-assisted substrate-linked directed evolution (caslide)
EP4458963A1 (en) * 2023-05-04 2024-11-06 Technische Universität Dresden Highly active crispr base editors obtained through cas-assisted substrate-linked directed evolution (caslide)
CN120290534A (zh) * 2024-01-10 2025-07-11 上海数因信科智能科技有限公司 腺嘌呤脱氨酶、包含其的碱基编辑器融合蛋白和碱基编辑器系统及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007765B1 (pt) * 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
AU2020215730A1 (en) * 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
WO2020160517A1 (en) * 2019-01-31 2020-08-06 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
WO2021022043A2 (en) * 2019-07-30 2021-02-04 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
WO2021042062A2 (en) * 2019-08-30 2021-03-04 Joung J Keith Combinatorial adenine and cytosine dna base editors
AU2020344547A1 (en) * 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same

Similar Documents

Publication Publication Date Title
JP2024511163A5 (https=)
JP2025170240A5 (https=)
US20230139474A1 (en) RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
JP7553110B2 (ja) エピゲノム編集のための組成物および方法
CN113631708B (zh) 编辑rna的方法和组合物
JP2022546608A5 (https=)
AU2019265019B2 (en) Methods of substituting pathogenic amino acids using programmable base editor systems
JP2023166400A5 (https=)
JP2022521460A5 (https=)
JP2022519507A5 (https=)
JP2025183226A5 (https=)
CN105916983A (zh) 用于高效且特异性靶向包含高度重复基序的dna序列的稀有切割核酸内切酶的设计
JP2022545950A5 (https=)
JP2024511131A5 (https=)
JP2024506375A5 (https=)
JP2023545497A5 (https=)
RU2020114785A (ru) Искусственная модификация генома для регуляции экспрессии гена
JP2023515670A5 (https=)
JP2025505732A5 (https=)
JP2021522825A5 (https=)
CN109929865A (zh) 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用
CN114599789A (zh) 人工合成mRNA及其利用
WO2025045078A1 (zh) 一种用于调控rna甲基化修饰的编辑系统及其应用
CN114144231A (zh) 用于治疗癌症的crispr方法
KR20240141024A (ko) E1347A DddAtox 변이체-TnpB fusion 단백질을 이용한 유전자 가위 시스템